Literature DB >> 12414976

Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides.

Jason J Coull1, Guocheng He, Christian Melander, Victor C Rucker, Peter B Dervan, David M Margolis.   

Abstract

The host factor LSF represses the human immunodeficiency virus type 1 long terminal repeat (LTR) by mediating recruitment of histone deacetylase. We show that pyrrole-imidazole polyamides targeted to the LTR can specifically block LSF binding both in vitro and within cells via direct access to chromatin, resulting in increased LTR expression.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12414976      PMCID： PMC136904          DOI： 10.1128/jvi.76.23.12349-12354.2002

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  17 in total

1.  A bioassay for HIV-1 based on Env-CD4 interaction.

Authors:  V Ciminale; B K Felber; M Campbell; G N Pavlakis
Journal:  AIDS Res Hum Retroviruses       Date:  1990-11       Impact factor: 2.205

2.  Anti-repression of RNA polymerase II transcription by pyrrole-imidazole polyamides.

Authors:  L A Dickinson; J W Trauger; E E Baird; P Ghazal; P B Dervan; J M Gottesfeld
Journal:  Biochemistry       Date:  1999-08-17       Impact factor: 3.162

3.  Inhibition of Ets-1 DNA binding and ternary complex formation between Ets-1, NF-kappaB, and DNA by a designed DNA-binding ligand.

Authors:  L A Dickinson; J W Trauger; E E Baird; P B Dervan; B J Graves; J M Gottesfeld
Journal:  J Biol Chem       Date:  1999-04-30       Impact factor: 5.157

4.  Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF.

Authors:  F Romerio; M N Gabriel; D M Margolis
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

5.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

Authors:  D Finzi; M Hermankova; T Pierson; L M Carruth; C Buck; R E Chaisson; T C Quinn; K Chadwick; J Margolick; R Brookmeyer; J Gallant; M Markowitz; D D Ho; D D Richman; R F Siliciano
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

6.  Histone acetyltransferases regulate HIV-1 enhancer activity in vitro.

Authors:  P L Sheridan; T P Mayall; E Verdin; K A Jones
Journal:  Genes Dev       Date:  1997-12-15       Impact factor: 11.361

7.  Inhibition of major-groove-binding proteins by pyrrole-imidazole polyamides with an Arg-Pro-Arg positive patch.

Authors:  R E Bremer; E E Baird; P B Dervan
Journal:  Chem Biol       Date:  1998-03

8.  Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat.

Authors:  Guocheng He; David M Margolis
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

9.  Activation of gene expression by small molecule transcription factors.

Authors:  A K Mapp; A Z Ansari; M Ptashne; P B Dervan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

10.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728
View more
  28 in total

Review 1.  Therapeutic modulation of endogenous gene function by agents with designed DNA-sequence specificities.

Authors:  Taco G Uil; Hidde J Haisma; Marianne G Rots
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

2.  Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection.

Authors:  Lillian Seu; Steffanie Sabbaj; Alexandra Duverger; Frederic Wagner; Joshua C Anderson; Elizabeth Davies; Frank Wolschendorf; Christopher D Willey; Michael S Saag; Paul Goepfert; Olaf Kutsch
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

3.  c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter.

Authors:  Guochun Jiang; Amy Espeseth; Daria J Hazuda; David M Margolis
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

4.  Cell cycle arrest in G2 induces human immunodeficiency virus type 1 transcriptional activation through histone acetylation and recruitment of CBP, NF-kappaB, and c-Jun to the long terminal repeat promoter.

Authors:  Sylvain Thierry; Vincent Marechal; Michelle Rosenzwajg; Michèle Sabbah; Gérard Redeuilh; Jean-Claude Nicolas; Joël Gozlan
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

5.  Transcription through the HIV-1 nucleosomes: effects of the PBAF complex in Tat activated transcription.

Authors:  Rebecca Easley; Lawrence Carpio; Luke Dannenberg; Soyun Choi; Dowser Alani; Rachel Van Duyne; Irene Guendel; Zachary Klase; Emmanuel Agbottah; Kylene Kehn-Hall; Fatah Kashanchi
Journal:  Virology       Date:  2010-09-30       Impact factor: 3.616

6.  Nuclear localization of pyrrole-imidazole polyamide-fluorescein conjugates in cell culture.

Authors:  Timothy P Best; Benjamin S Edelson; Nicholas G Nickols; Peter B Dervan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

7.  Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.

Authors:  Sophie Reuse; Miriam Calao; Kabamba Kabeya; Allan Guiguen; Jean-Stéphane Gatot; Vincent Quivy; Caroline Vanhulle; Aurélia Lamine; Dolores Vaira; Dominique Demonte; Valérie Martinelli; Emmanuelle Veithen; Thomas Cherrier; Véronique Avettand; Solène Poutrel; Jacques Piette; Yvan de Launoit; Michel Moutschen; Arsène Burny; Christine Rouzioux; Stéphane De Wit; Georges Herbein; Olivier Rohr; Yves Collette; Olivier Lambotte; Nathan Clumeck; Carine Van Lint
Journal:  PLoS One       Date:  2009-06-30       Impact factor: 3.240

Review 8.  Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.

Authors:  Laurence Colin; Carine Van Lint
Journal:  Retrovirology       Date:  2009-12-04       Impact factor: 4.602

9.  Cell line-dependent variability in HIV activation employing DNMT inhibitors.

Authors:  Guerau Fernandez; Steven L Zeichner
Journal:  Virol J       Date:  2010-10-13       Impact factor: 4.099

Review 10.  Latency reversal and viral clearance to cure HIV-1.

Authors:  David M Margolis; J Victor Garcia; Daria J Hazuda; Barton F Haynes
Journal:  Science       Date:  2016-07-22       Impact factor: 47.728
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.